Miami Jewish Home and Hospital, Berma Research Group and Segal Institute for Clinical Research Enrolling Local Patients in Study of Investigational Therapy to Treat Alzheimer... ( MIAMI Nov. 12 /- The Miami Jewish...)

HOME >> MEDICINE >> TECHNOLOGY

Miami Jewish Home and Hospital, Berma Research Group and Segal Institute for Clinical Research Enrolling Local Patients in Study of Investigational Therapy to Treat Alzheimer's Disease

Date:11/12/2008

MIAMI, Nov. 12 /PRNewswire/ -- The Miami Jewish Home and Hospital, Berma Research Group, and Segal Institute for Clinical Research today announced that they are actively enrolling patients in the CONNECTION study, a Phase 3 clinical trial that is evaluating the safety and efficacy of the investigational drug Dimebon as a treatment for mild-to-moderate Alzheimer's disease.

According to new estimates from the Alzheimer's Association, more than 5 million people in the United States are living with Alzheimer's disease, a progressive, debilitating and deadly disease that destroys brain cells and affects areas of the brain involved in memory, cognition, judgment, language and behavior. As the baby boomer population ages, the incidence of Alzheimer's disease is expected to increase dramatically. Currently available therapies for Alzheimer's treat the symptoms with modest effect, and there is no evidence that these medications alter the course of the underlying disease process.

"New therapies are urgently needed to more effectively treat the symptoms of Alzheimer's disease," said Dr. Marc Agronin, director of mental health services at the Miami Jewish Home and Hospital and associate professor of psychiatry at the University of Miami Miller School of Medicine. "Results from a previous study of Dimebon in Alzheimer's disease were encouraging, and we look forward to further assessing Dimebon's promise in the fight against Alzheimer's disease in the CONNECTION study. We encourage local patients and caregivers to learn more about this trial."

About Dimebon

Dimebon is an investigational therapy in clinical development for the treatment of Alzheimer's disease. It targets Alzheimer's disease differently than currently available therapies. Mitochondria (a cell's primary source of energy) are the target of Dimebon's mechanism of action.

Medivation, Inc., the company developing Dimebon and sponsoring the CONNECTION study, previously announced
'/>"/>

SOURCE Miami Jewish Home & Hospital; Berma Research Group; SegalInstitute
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3
Related medicine technology :

1. University of Miami Team Confirms Value of Monitoring Cell-Mediated Immunity Pre- and Post-Transplant in Management of Kidney Transplant Recipients
2. Miami Plastic Surgeon Offers Hope to Acne Scarred Patients
3. Uncontrolled Blood Pressure Highest Among Hispanics, Prompting New Hypertension Project in Miami
4. National Jewish Health and Roche Diagnostics Corporation Reach Agreement to Pursue Environmental Molecular Diagnostics Opportunities
5. National Jewish, Brigham and Womens Awarded $37 Million to Identify Genes and Other Risk Factors that Influence the Development of COPD
6. Sarah Cannon Research Institute Selects OmniComm Systems Electronic Data Capture Solution, TrialMaster(TM), for Clinical Trials Management
7. Michael J. Fox Foundation Announces $11 Million in 2009 Funding for Translational, Pre-Clinical and Clinical Parkinsons Disease Research
8. SELECT TRIAL Used Selenomethionine Instead of High-Selenium Yeast, SelenoExcell(R) - Previous Research has Shown SelenoExcell(R) Supplementation to Reduce Lung, Colon and Prostate Cancers by as Much as 63%, Says Cypress Systems, Inc.
9. Premier Research Honored as Clinical Research Team of the Year at 2008 GCPj Awards
10. Nuvo Research presents positive Phase III study results for Pennsaid at leading rheumatology conference
11. Alzheimers Association Grant Furthers Successful Research at UMass Lowell

Post Your Comments:

(Date:11/9/2009)..., NATICK, Mass., Nov. 9 /PRNewswire-FirstCall/ ...ay announced its schedule of events at the 38th an...logy (AAGL), which runs from November 15-19 in Orl...will be presented featuring the Company,s Urology/...truction systems and mid-urethral sling systems us...

(Date:11/9/2009)..., NEW YORK, Nov. 9 /PRNewswire-Asia-FirstCa...E: AOB ), ("the Company" or "AOBO"), a pharmaceut... the development, manufacture and,commercializatio...unter ("OTC"),products, today announced that it pl...s on Monday, November 16, 2009, after the market c...

(Date:11/9/2009)..., SAN DIEGO, Nov. 9, 2009 /PRNewswire-FirstCall...today reported financial results for the third qua...d a lower net loss allocable to common stockholder...r $0.38 per share, compared to a net loss allocabl...008 of $56.2 million, or $0.76 per share, and a ne...

[0] Boston Scientific's Urology/Gynecology Products Featured in Studies at Global Congress [0] American Oriental Bioengineering to Report Third Quarter 2009 Financial Results on November 16, 2009 [0] Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments

...E)--May 24, 2007 - Cyclacel,Pharmaceuticals, Inc. ... it will report results from a Phase I pharmacolog...available nucleoside analog,in patients with adva... at the American Society of Clinical Oncology,s (A... Details of the presentation,are as follows:, Abst...

... - HepaLife Technologies, Inc.,(OTCBB:HPLF) (FWB:H...ic presentation of its cell based PBS-1 technology... "Options for the,Control of Influenza VI Conferen...da., Entitled "High titer growth of human and avia...o cell line without the need for,exogenous proteas...

Other Medicine Technology:Cyclacel Pharmaceuticals to Report Sapacitabine Phase I Study,Results at the American Society of Clinical Oncology Annual Meeting 2 Cyclacel Pharmaceuticals to Report Sapacitabine Phase I Study,Results at the American Society of Clinical Oncology Annual Meeting 3 HepaLife Announces Scientific Presentation of PBS-1 Cell Line at,International Influenza Meeting 2 HepaLife Announces Scientific Presentation of PBS-1 Cell Line at,International Influenza Meeting 3 HepaLife Announces Scientific Presentation of PBS-1 Cell Line at,International Influenza Meeting 4 HepaLife Announces Scientific Presentation of PBS-1 Cell Line at,International Influenza Meeting 5

Cyclacel Pharmaceuticals to Report Sapacitabine Phase I Study,Results at the American Society of Clinical Oncology Annual Meeting HepaLife Announces Scientific Presentation of PBS-1 Cell Line at,International Influenza Meeting

(Date:11/9/2009)...na, Nov. 9 /PRNewswire-Asia-FirstCall/ -- Mindray ...ing developer, manufacturer and,marketer of medica...unaudited,financial results for the third quarter ...Highlights for Operations as of September 30, 2009...1 million, an increase of, 3.1% over the thi...

(Date:11/9/2009)...ks President Obama,s promise to not expand abortio... Bishops still concerned for poor, elderly ,, ...inal Francis George of Chicago, president of the U...d the November 7 decision of the U.S. House of Rep...oney from paying for elective abortions. ,, In...

(Date:11/9/2009)... Studying Genetic Variance Across the World is C... (Vocus) November 9, 2009 --...xtraordinarily valuable when analyzing and interpr...ics study that scanned the genomes of 4,000 peopl...rences, Drs. Chao Tian and Michael F. Seldin of th...

(Date:11/9/2009)...new cells regained sexual function, study says,...Researchers were able to restore sexual function t...le tissue in the lab and implanting it, a new stud...ys off, researchers say the technique could one da...men. , "We were able to show the tissue was abl...

(Date:11/9/2009)... Course, to be Offered in April 2010, Provides F... Cambridge, MA (Vocus) November 9,...an Rights (PHR) first inspected a suspected mass ...d he would need a team of experts to help interpre...perly was a key first step in securing evidence of...

[0] Mindray Announces Third Quarter 2009 Financial Results [0] Cardinal George Lauds House Action to Ban Federal Funds for Abortion; Promises Vigilance as Senate Pursues Health Care Reform, Wary About Affect on Poor, Elderly [0] News from the November/December Issue of Molecular Medicine [0] Scientists Grow New Penile Tissue in the Lab [2] Physicians for Human Rights Offers Training in Crime Scene Documentation

...N.J., Dec. 12 Alfacell Corporation (Nasdaq: AC...president, chief financial officer and corporate s...s of today. Mr. Kenyon will remain on the board o... Kenyon has accepted a full time position as execu...

...ass., Dec. 12 Millennium Research Group (MRG) ana...ished G lobal Markets for Hyaluronic Acid Viscos...fer extensive expertise on the recent FDA premarke...s available to comment on: , , , , ...

..., Dec. 12 Ogilvy Public Relations Worldwide (Ogi... announced today that it has been awarded a five-y...with the National Cancer Institute (NCI), Office o...,s life sciences consulting subsidiary, Feinstein ...

...hase 3 Program Expected to Begin in December - , ...rmaceuticals, a division of Wyeth (NYSE: WYE ), ...inical trial of neratinib (HKI-272) in women with ...the ErbB-2 receptor (also known as HER-2 or Neu). ...

...s not sure whether one causes the other, or one is...2 (HealthDay News) -- Adults who have panic disord...t attacks and heart disease, but not heart-related...than 347,000 adults without the condition. , Peopl...

...ec. 12 The Female Health Company (NYSE Alternex...Administration,s (FDA) Obstetrics and Gynecology D...at the company,s second-generation female condom, ...ondition that the FC2 Female Condom,s instructions...

Other Medicine News:Health News:Alfacell Announces Management Update 2 Health News:Alfacell Announces Management Update 3 Health News:Millennium Research Group Analyst Available to Comment on FDA's Premarket Approval Recommendation of Genzyme Biosurgery's Synvisc Single-Injection Product for the Knee 2 Health News:National Cancer Institute Selects Ogilvy Public Relations Worldwide for Comprehensive Multi-Year Communications Support 2 Health News:Wyeth Announces Positive Data from Phase 2 Study of Neratinib in Advanced HER-2-Positive Breast Cancer 2 Health News:Wyeth Announces Positive Data from Phase 2 Study of Neratinib in Advanced HER-2-Positive Breast Cancer 3 Health News:Wyeth Announces Positive Data from Phase 2 Study of Neratinib in Advanced HER-2-Positive Breast Cancer 4 Health News:Panic Disorder Linked to Higher Risk of Heart Disease 2 Health News:FDA Advisory Committee Votes Unanimously that FC2 Female Condom(R) is Approvable 2 Health News:FDA Advisory Committee Votes Unanimously that FC2 Female Condom(R) is Approvable 3 Health News:FDA Advisory Committee Votes Unanimously that FC2 Female Condom(R) is Approvable 4 Health News:FDA Advisory Committee Votes Unanimously that FC2 Female Condom(R) is Approvable 5

Alfacell Announces Management Update Millennium Research Group Analyst Available to Comment on FDA's Premarket Approval Recommendation of Genzyme Biosurgery's Synvisc Single-Injection Product for the Knee National Cancer Institute Selects Ogilvy Public Relations Worldwide for Comprehensive Multi-Year Communications Support Wyeth Announces Positive Data from Phase 2 Study of Neratinib in Advanced HER-2-Positive Breast Cancer Panic Disorder Linked to Higher Risk of Heart Disease FDA Advisory Committee Votes Unanimously that FC2 Female Condom(R) is Approvable

EBI OsteoGen™-M (Mesh Cathode)

Interference Screws

...crew is indicated for graft fixation in Orthopaedi...s with bone-patellar tendon-bone or soft tissue au...es easy and atraumatic insertions with excellent g...-Reinforced 96L/4D copolymer combines optimal stre...

PHANTOM SofThread Cannulated Interference Screws

Medicine Products:

EBI OsteoGen™-M (Mesh Cathode)Interference Screws SmartScrew ACL PHANTOM SofThread Cannulated Interference Screws

Miami Jewish Home and Hospital, Berma Research Group and Segal Institute for Clinical Research Enrolling Local Patients in Study of Investigational Therapy to Treat Alzheimer...( MIAMI Nov. 12 /- The Miami Jewish...),Health